WU
MRSN

Washington University’s Mersana Therapeutics MRSN Stock Holding History

Washington University’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-375
Closed -$43K – 10
2022
Q2 		$43K Buy
+375
New +$35.3K 0.02% 11

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Washington University's MRSN Position: Q3 2022 in Review

Washington University sold out of Mersana Therapeutics (MRSN) in Q3 2022, closing a stake of 375 shares — an estimated $43K sold.

Washington University first reported a position in MRSN in Q2 2022 and held it in 1 quarter. The position peaked at $43K in Q2 2022. 152 funds tracked by Wall St. Rank hold MRSN as of Q3 2022.

  • Washington University reported no remaining Mersana Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Washington University sold 375 Mersana Therapeutics shares in Q3 2022, an estimated $43K.
  • Washington University first reported a position in Mersana Therapeutics in Q2 2022 and held it in 1 quarter.
  • Washington University's Mersana Therapeutics position peaked at $43K in Q2 2022.
  • 152 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2022.

Based on Washington University's 13F filing for Q3 2022, filed 14 Nov 2022.